Recurrence of duodenal ulcer under continuous antisecretory treatment: an approach to the detection of predictive markers

Am J Gastroenterol. 1984 Nov;79(11):831-4.

Abstract

Seventy consecutive duodenal ulcer patients endoscopically followed up and treated after ulcer scarring with maintenance dosages of effective antisecretory drugs for 1 year were studied in order to identify the factors associated with ulcer relapse. Logrank test, discriminant analysis (Rao's method), and chi 2 were used in evaluating the results. Nineteen patients (27.1%) relapsed. Duodenal ulcer was found to relapse more frequently in patients with total serum pepsinogen more than 109 micrograms tyr X ml-1 X 24 h-1 and in patients with maximal acid output more than 60 mmol/h (Logrank test; both p less than 0.025). Discriminant analysis showed that blood group, age at onset of the disease, and sex were together useful in recognizing subjects relapsing within 6 months' maintenance treatment (77.1% cases correctly classified); age at onset of the disease, alcohol intake, and smoking habit were together useful in picking out subjects relapsing throughout the entire observation period (1 year) (61.76% cases correctly classified). Our data suggest that: 1) duodenal ulcer subjects with elevated serum pepsinogen or maximal acid output are significantly more prone to relapse than patients with normal or slightly increased values; 2) genetic and acquired factors (such as blood group A, early onset of the disease, male sex, alcohol intake, and cigarette consumption) may have a role in influencing ulcer relapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Alcohol Drinking
  • Anti-Ulcer Agents / therapeutic use*
  • Benzodiazepinones / therapeutic use
  • Blood Group Antigens
  • Cimetidine / therapeutic use
  • Duodenal Ulcer / blood
  • Duodenal Ulcer / drug therapy*
  • Duodenal Ulcer / etiology
  • Duodenal Ulcer / metabolism
  • Female
  • Follow-Up Studies
  • Gastric Acid / metabolism
  • Humans
  • Male
  • Middle Aged
  • Pepsinogens / blood
  • Pirenzepine
  • Ranitidine / therapeutic use
  • Recurrence
  • Sex Factors
  • Smoking

Substances

  • Anti-Ulcer Agents
  • Benzodiazepinones
  • Blood Group Antigens
  • Pepsinogens
  • Pirenzepine
  • Cimetidine
  • Ranitidine